M.J. Rubio Pérez

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

B.J. Monk, Maria Pilar Barretina-Ginesta, Bhavana Pothuri et al. · Annals of Oncology · 2024 · 150 citations · Full text

Medicine, Oncology, Pharmacology +17

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Christian Marth, Richard G. Moore, Mariusz Bidziński et al. · Journal of Clinical Oncology · 2024 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

Andrés Poveda, Stéphanie Lheureux, Nicoletta Colombo et al. · Gynecologic Oncology · 2022 · 57 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer

Yolanda García García, Ana de Juan Ferré, César Mendiola et al. · International Journal of Gynecological Cancer · 2019 · 56 citations

Medicine, Gynecology, Oncology +17

DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.

Philipp Harter, Mariusz Bidziński, Nicoletta Colombo et al. · Journal of Clinical Oncology · 2019 · 46 citations

Medicine, Pharmacology, Pharmacotherapy +17